Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
102.0
Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
360.0
Receiving any other investigational agent
48.0
Receiving any other investigational agent
224.0
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
102.0
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
42.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
72.0
Prior investigational immunotherapy
80.0
Use of an investigational agent within the past 30 days
104.0
TREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumorï¿½s mutation/aberrant pathway
700.0
Subjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registration
52.0
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
54.0
Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
40.0
Patients must NOT receive concurrent anti-cancer therapy or investigational agent unless specified in protocol
600.0
Patients who are receiving any other investigational agent(s)
340.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
90.0
Patients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
36.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
135.0
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is required
35.0
Other investigational agent within 3 weeks prior to initiation of study therapy
30.0
No investigational agent within 21 days prior to registration
110.0
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
50.0
Patient is receiving another investigational agent for the treatment of cancer
188.0
Patients who have previously received temsirolimus, another mTOR inhibitor, or any other investigational agent
337.0
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
24.0
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greater
98.0
Patients who are receiving any other investigational agent
47.0
